Nemes Rush Group LLC Tg Therapeutics, Inc. Call Options Transaction History
Nemes Rush Group LLC
- $728 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TGTX
# of Institutions
306Shares Held
92.8MCall Options Held
1.9MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA13.7MShares$334 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$277 Million0.0% of portfolio
-
State Street Corp Boston, MA6.7MShares$163 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.65MShares$88.8 Million6.57% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.24MShares$79 Million0.07% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $3.54B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...